Search Result

Results for "

brown+adipose+tissue

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acetyl-CoA Carboxylase (2) Adrenergic Receptor (3) ATP Synthase (1) Endogenous Metabolite (5) Epoxide Hydrolase (1) FXR (2) G protein-coupled Bile Acid Receptor 1 (4) HDAC (1) Insecticide (1) Isotope-Labeled Compounds (3) PGC-1α (1) PPAR (1) Progesterone Receptor (1) PROTACs (1) Reference Standards (1) α-synuclein (1)
By Research Areas:	Cancer (1) Infection (1) Inflammation/Immunology (1) Metabolic Disease (14)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-116771A

CL 316243 Maximum Cited Publications 24 Publications Verification	Adrenergic Receptor	Metabolic Disease
CL316243 is a highly potent selective β3-adrenoceptor agonist with a EC₅₀ of 3 nM, but is an extremely poor to β1/2- receptors .CL316243 is a effective stimulant of adipocyte lipolysis and increases brown adipose tissue thermogenesis and metabolic rate . CL316243 has the potential for the treatment obesity, diabetes and urge urinary incontinence .

HY-N0593S

Deoxycholic acid-d4 1 Publications Verification	Isotope-Labeled Compounds G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid-d₄ is the deuterium labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-N0468

Rebaudioside D 1 Publications Verification	FXR Acetyl-CoA Carboxylase	Metabolic Disease
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-116003

12,13-DiHOME	Endogenous Metabolite	Metabolic Disease
12,13-DiHOME is a stimulator of Brown adipose tissue (BAT), as well as a thermogenic lipokine that activates BAT in response to cold. (±)12,13-DiHOME activates BAT fuel uptake and enhances cold tolerance, via promoting the translocation of the FA transporters FATP1 and CD36 to the cell membrane. (±)12,13-DiHOME can be used for research of metabolic disorders .

HY-135115

Oleuropein Aglycone 3,4-DHPEA-EA	α-synuclein HDAC Adrenergic Receptor	Inflammation/Immunology
Oleuropein Aglycone (3,4-DHPEA-EA) is a polyphenol and the aglycone form of oleuropein (HY-N0292), formed by enzymatic, acidic or acetylated hydrolysis of oleuropein. Dietary intake of oleuropein Aglycone (50 mg/kg diet) increases the number of neuronal autophagic vesicles, reverses cognitive deficits in the TgCRND8 transgenic mouse model of Alzheimer's disease, and reduces the levels of histone deacetylase 2 (HDAC2) in the cortex and hippocampus. Oleuropein Aglycone increases urinary norepinephrine, interscapular brown adipose tissue epinephrine, and UCP1 protein levels, and reduced plasma leptin levels and total abdominal adipose tissue weight in a rat model of high-fat diet-induced obesity. Oleuropein Aglycone also reduced lung neutrophil infiltration, lipid peroxidation, and IL-1β levels in a mouse model of carrageenan-induced pleurisy.

HY-116771

CL 316243 free acid Maximum Cited Publications 24 Publications Verification	Adrenergic Receptor	Metabolic Disease
CL316243 free acid is a highly potent selective β3-adrenoceptor agonist with a EC₅₀ of 3 nM, but is an extremely poor to β1/2- receptors. CL316243 free acid is a effective stimulant of adipocyte lipolysis and increases brown adipose tissue thermogenesis and metabolic rate. CL316243 free acid has the potential for the treatment obesity, diabetes and urge urinary incontinence .

HY-N0593S1

Deoxycholic acid-d5	Isotope-Labeled Compounds G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid-d₅ is the deuterium labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-N0593S3

Deoxycholic acid-13C Cholanoic Acid-¹³C; Desoxycholic acid-¹³C	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid- ¹³C is the ¹³C-labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-N0593S2

Deoxycholic acid-d6 Cholanoic acid-d₆; Desoxycholic acid-d₆	Isotope-Labeled Compounds G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid-d₆ is the deuterium labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-148973

ZW290	ATP Synthase	Metabolic Disease
ZW290 is a compound to activate brown adipose tissue (BAT) thermogenic function. ZW290 increases the expression of uncoupling Protein 1 (UCP1) protein and inhibits ATP synthesis in BAT .

HY-N0468R

Rebaudioside D (Standard)	Reference Standards Acetyl-CoA Carboxylase FXR	Metabolic Disease
Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-159494

PROTAC sEH-degrader-1	PROTACs Epoxide Hydrolase	Metabolic Disease
sEH-degrader-1 (Compound 8) serves as an inhibitor for sEH, with IC₅₀ values of 3.8 nM and 210 nM against hsEH and msEH respectively. sEH-degrader-1 can effectively degrade sEH in mouse liver and brown adipose tissue (Red: UC-1728 (HY-114266), black: linker (HY-W248248), Blue: Thalidomide-5-piperazine (HY-W834174)) .

HY-11032

SM-350300	Others	Metabolic Disease
SM-350300 is a glucoprotein. SM-350300 stimulates lipolysis in white adipocytes by activating the cyclic AMP (cAMP) pathway, and upregulates the expression of lipolytic enzymes and uncoupling proteins (UCP1, UCP3) in brown adipose tissue (BAT) and white adipose tissue (WAT). SM-350300 reduces body weight by decreasing carcass fat while increasing lean muscle mass in metabolic disorder models. SM-350300 can be used for the study of metabolic disorders including obesity, type 2 diabetes, and cachexia .

HY-126969

C333H	PPAR	Metabolic Disease
C333H is a selective PPARγ modulator with insulin-sensitizing and hypoglycemic activities. C333H exhibits similar insulin-sensitizing effects to thiazolidinediones (TZDs) in diabetic mouse models without significantly increasing body weight or adipose tissue weight. C333H increases circulating high molecular weight adiponectin isoform levels in diabetic db/db mice, reduces serine phosphorylation of PPARγ 273 in brown adipose tissue, and selectively modulates the expression of specific PPARγ target genes in adipose tissue. Express. C333H exhibits weak recruitment of co-activators and weak dissociation of co-repressors in vitro. These properties suggest that C333H may be a potential inhibitor of type 2 diabetes .

HY-186011

CPAG-1	Progesterone Receptor	Metabolic Disease
CPAG-1 is a small-molecule activator of progesterone receptor membrane component 2 (PGRMC2). CPAG-1 can enhance mitochondrial heme delivery to the nucleus mediated by PGRMC2 and activate genes related to heat production in brown adipose tissue (BAT), such as Ucp1 and Pgc-1α, and reduce lipid accumulation in BAT. CPAG-1 reduce fasting blood sugar and insulin levels, and improve glucose tolerance and insulin sensitivity. CPAG-1 can be used for research of type 2 diabetes .

HY-171722

Ascr#10 Asc-C9	Insecticide PGC-1α	Infection Cancer
Ascr#10 (Asc-C9) is an orally active thermogenesis inducer and insecticide that can be obtained from Monochamus alternatus. Ascr#10 binds to the insect adipokinetic hormone (AKH) receptor (K_a=272 µM) and stimulates mitochondrial biogenesis via the PGC1α-UCP4 axis. Consequently, Ascr#10 induces UCP4-mediated uncoupled respiration, reduces the ATP/ADP ratio and accelerates lipid mobilization, thereby driving the thermogenesis process. Ascr#10 delays pupation and exerts specific chemotaxis toward dispersive fourth-stage pinewood nematode LIV larvae. Ascr#10 promotes cold acclimation of Monochamus alternatus larvae through metabolic inhibition and cryoprotectant accumulation, enhancing their survival rate under cold stress. Ascr#10 also induces browning of white adipose tissue and activates brown adipose tissue in mice, thereby helping the body resist cold and tumor growth. Ascr#10 can be widely applied to research related to pine wilt disease, lung tumors and cold stress .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0468

Rebaudioside D 1 Publications Verification	Structural Classification other families Classification of Application Fields Terpenoids Metabolic Disease Diterpenoids Plants Disease Research Fields Sweeteners Source Classification Food Research	FXR Acetyl-CoA Carboxylase
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-116003

12,13-DiHOME	Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
12,13-DiHOME is a stimulator of Brown adipose tissue (BAT), as well as a thermogenic lipokine that activates BAT in response to cold. (±)12,13-DiHOME activates BAT fuel uptake and enhances cold tolerance, via promoting the translocation of the FA transporters FATP1 and CD36 to the cell membrane. (±)12,13-DiHOME can be used for research of metabolic disorders .

HY-N0468R

Rebaudioside D (Standard)	Structural Classification other families Terpenoids Diterpenoids Plants Source Classification	Reference Standards Acetyl-CoA Carboxylase FXR
Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

Cat. No.	Product Name	Chemical Structure

HY-N0593S

Deoxycholic acid-d4 1 Publications Verification
Deoxycholic acid-d₄ is the deuterium labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-N0593S1

Deoxycholic acid-d5
Deoxycholic acid-d₅ is the deuterium labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-N0593S3

Deoxycholic acid-13C
Deoxycholic acid- ¹³C is the ¹³C-labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-N0593S2

Deoxycholic acid-d6
Deoxycholic acid-d₆ is the deuterium labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

brown+adipose+tissue

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products